5-Amino-1MQ 50mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule — not a peptide — that selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in fat tissue. In animal and cell studies, blocking NNMT is theorized to raise intracellular NAD+ and activate SIRT1, which researchers have linked to fat oxidation and preserved lean mass[1][2]. It is not FDA-approved for anything and has no completed human clinical trials — every effect below is preclinical (rodent/cell) only. Note also that 5-Amino-1MQ is well documented as orally bioavailable and is usually sold and dosed as an oral capsule; the subcutaneous approach on this page is this site’s framing, not the standard route. Presented for research and educational use only.

Add 4.0 mL bacteriostatic water to one 50 mg vial → 12.5 mg/mL, a clean concentration for accurate dosing.
2.5–5 mg per day (subcutaneous in this framing), once daily or split as 2.5 mg twice daily.
At 12.5 mg/mL, 1 unit = 0.125 mg; 2.5 mg = 20 units and 5 mg = 40 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and protect from light.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution with simple unit math, step by step

Subcutaneous Approach (4 mL = 12.5 mg/mL)

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Days 1–2 (Ramp)	2.5 mg once daily	20 units (0.20 mL)
Days 3+ (Standard)	5 mg once daily	40 units (0.40 mL)
Alternative (BID)	2.5 mg twice daily	20 units (0.20 mL) × 2

Reconstitute: Add 4.0 mL bacteriostatic water to one 50 mg vial → final concentration 12.5 mg/mL.
Typical daily range: 2.5–5 mg per day — 2.5 mg/day to start, increasing to 5 mg/day, or split as 2.5 mg twice daily.
Easy measuring: At 12.5 mg/mL, 1 unit = 0.01 mL = 0.125 mg on a U-100 syringe. Units = mg ÷ 0.125.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F), protect from light, and use within 2–4 weeks.
Frequency: one or two subcutaneous injections per day in this framing. Because the compound’s reported plasma half-life is roughly 3.8–6.9 hours[4], twice-daily dosing may give more sustained NNMT inhibition. One 50 mg vial provides roughly 10–20 days of material at these research doses. These figures come from preclinical and pharmacokinetic literature, not from approved human dosing — and note the standard route for this molecule is oral.

Reconstitution Steps

Remove the vial from freezer storage (−20 °C / −4 °F) and let it equilibrate at room temperature for 15–20 minutes.

Draw 4.0 mL of bacteriostatic water into a sterile syringe and release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — the solution should be clear. Don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light; use within 2–4 weeks.
The 4.0 mL fill gives a clean 12.5 mg/mL so each milligram maps to whole insulin units (1 unit = 0.125 mg). Do not freeze the reconstituted solution.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume research use with the 50 mg vial format at about 5 mg/day.

A 50 mg vial covers roughly 10 days at 5 mg/day, so plan about one vial per 1–2 weeks.
1 week (5 mg/day): ~1 vial
2 weeks (5 mg/day): ~1 vial
4 weeks (5 mg/day): ~2 vials
Per injection: 1 syringe
1 week (once daily): ~7 syringes
1 week (BID): ~14 syringes
4 weeks (once daily): ~28 syringes
Use ~4.0 mL per 50 mg vial for reconstitution.
1–2 weeks (1 vial): ~4 mL → 1 bottle
4 weeks (2 vials): ~8 mL → 1 bottle
One for the vial stopper + one for the injection site each administration.
Per injection: 2 swabs
4 weeks (once daily): ~56 swabs → 1 box

Protocol Overview

A concise summary of the once- or twice-daily regimen, drawn from preclinical reference material.

▪Goal: Inhibit NNMT to raise intracellular NAD+ and activate SIRT1, theorized to support fat metabolism and preserve lean mass — effects reported in animal and cell studies, not established in humans[1][5].
▪Schedule: Once-daily, or split twice daily, in this subcutaneous framing — though the molecule’s standard route is oral.
▪Dose Range: 2.5 mg/day to start, increasing toward 5 mg/day; alternatively 2.5 mg twice daily.
▪Reconstitution: 4.0 mL bacteriostatic water per 50 mg vial gives 12.5 mg/mL (1 unit = 0.125 mg).
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C, protect from light, and do not freeze the solution.

Dosing Protocol

A suggested daily approach based on preclinical reference doses for this NNMT inhibitor.

▪Start: Begin at 2.5 mg once daily for the first 1–2 days to gauge tolerability.
▪Standard: Move to 5 mg once daily from day 3 onward.
▪Split option: Given the ~3.8–6.9 h half-life, 2.5 mg twice daily may sustain NNMT inhibition more evenly.
▪Cycle length: Research schedules commonly run multi-week cycles; a single 50 mg vial supplies ~10–20 days.
▪Timing: Administer at consistent times each day and rotate injection sites systematically.

Storage Instructions

Correct storage preserves the compound’s stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[9].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F), protect from light, and use within about 2–4 weeks; do not freeze the mixed solution.
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[12].
▪Route note: 5-Amino-1MQ is well documented as orally bioavailable and is typically sold and dosed as an oral capsule. The subcutaneous approach here is this site’s framing, not the established route[4].
▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
▪Regulatory note: 5-Amino-1MQ is not FDA-approved for any use and has not been studied in completed human clinical trials; it is an investigational research chemical.

How This Works

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule — not a peptide — that selectively inhibits nicotinamide N-methyltransferase (NNMT)[1]. NNMT methylates nicotinamide (a form of vitamin B3) using S-adenosylmethionine (SAM) as the methyl donor. In obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and lowering NAD+ availability[2].

By inhibiting NNMT, 5-Amino-1MQ is theorized to spare nicotinamide for NAD+ synthesis, raising intracellular NAD+ and activating SIRT1 (Sirtuin 1) pathways tied to mitochondrial biogenesis and fat oxidation[3]. In rodent and cell work, NNMT knockdown or inhibition has been described as protecting against diet-induced weight gain and improving metabolic measures without reducing food intake[5][6].
Some preclinical work has also reported preserved or enhanced lean muscle — for example, greater grip strength in aged mice when combined with exercise[7]. These remain animal and cell-culture findings.
Important caveat: there are no completed human clinical trials of 5-Amino-1MQ. Every fat-metabolism, NAD+, SIRT1 and lean-mass effect described above is preclinical (rodent or cell) only and should be read as a hypothesis, not an established human benefit. Nothing here implies weight-loss efficacy in people.
Route: 5-Amino-1MQ is well documented as orally bioavailable and is usually sold and dosed as an oral capsule (commonly ~50–150 mg/day in product use)[4]. This page reframes it as a subcutaneous injection, which is the site’s choice; the standard route for this molecule is oral.
5-Amino-1MQ is not an approved medicine. It is an unapproved investigational research chemical presented here for research and educational purposes only.

Lifestyle Factors

Habits that may support metabolic health alongside the protocol.

▪Nutrition: Keep protein intake adequate and overall diet balanced to support metabolism and lean mass.
▪Activity: Pair regular resistance and aerobic exercise with the protocol — preclinical lean-mass effects were strongest when combined with exercise.
▪Sleep: Aim for 7–9 hours to support the body’s natural metabolic and repair processes.
▪Stress: Manage stress with evidence-based practices, since it influences overall metabolic health.

Potential Benefits & Side Effects

What preclinical literature describes. There is no completed human evidence, and individual results are unknown.

▪Fat metabolism: Animal models report reductions in fat mass while lean muscle is preserved[5][6].
▪NAD+ / SIRT1: Associated with elevated NAD+ and SIRT1 activation in preclinical studies[2][3].
▪Muscle strength: Enhanced grip strength observed in aged mice when combined with exercise[7].
▪Note on humans: These benefits are not established in humans — no completed clinical trials exist[1].
▪Mild, anecdotal: Occasional reports of mild headache, transient jitteriness, or injection-site reactions.
▪Injection-site reactions: Redness, tenderness or soreness can occur in this SC framing; rotating sites helps.
▪Unknown long-term profile: No human safety data, so caution and monitoring are advised.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[10][11]. (The standard route for this molecule is oral; this covers the SC framing used on this page.)

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[11].
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[10].
▪Skip aspiration for subcutaneous shots — it isn’t needed[10].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy[12].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research compounds, we point researchers to Prime Lab Peptides.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality compounds.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for 5-Amino-1MQ 50mg.

5-Amino-1MQ (50 mg Vial) Dosage Protocol Open source
1 Nature Medicine (2014) Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (preclinical). View Source ↗ Open source
2 PMC (2024) NNMT inhibition mitigates obesity-related metabolic dysfunctions in animal models. View Source ↗ Open source
3 Frontiers in Pharmacology (2024) NNMT as a candidate therapeutic target for metabolic syndrome (review). View Source ↗ Open source
4 PubMed (2021) LC-MS/MS assay for 5-amino-1-methylquinolinium: pharmacokinetics and oral bioavailability. View Source ↗ Open source
5 ResearchGate (2021) Combined NNMT inhibition and reduced-calorie diet normalizes body composition in obese mice. View Source ↗ Open source
6 PMC (2022) Reduced-calorie diet with NNMT inhibition establishes a distinct microbiome in DIO mice. View Source ↗ Open source
7 NMN.com / Scientific Reports NNMT inhibition and muscle strength: enhanced grip strength with exercise (preclinical). View Source ↗ Open source
8 Swolverine 5-Amino-1MQ mechanism, benefits, stacking and cycling overview (educational). View Source ↗ Open source
9 PMC Subcutaneous drug injection review: pharmacologic considerations. View Source ↗ Open source
10 CDC Vaccine administration: subcutaneous route (angle/site; no aspiration). View Source ↗ Open source
11 CDC (Subcut Injection PDF) Technique diagram and site guidance for subcutaneous injections. View Source ↗ Open source
12 NCBI Bookshelf Best practices for injection: asepsis, preparation and administration. View Source ↗ Open source
13 Journal of Medicinal Chemistry (ACS) Bisubstrate inhibitors of NNMT with enhanced activity. View Source ↗ Open source
14 PMC NNMT: a bad actor in fat makes good in liver (review of NNMT biology). View Source ↗ Open source
15 Prime Lab Peptides Research-grade supplier reference for high-purity compounds and batch documentation. View Source ↗ Open source

Contents